Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout

S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges

(2016) Johannes Carl Christoph Lenz et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Dolutegravir inhibits HIV-1 Env evolution in primary human cells

(2015) Thibault Mesplède et al.   AIDS

Integrase inhibitor reversal dynamics indicate unintegrated HIV-1 dna initiate de novo integration

(2015) Sylvain Thierry et al.   Retrovirology

Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors

(2014) Maureen Oliveira et al.   AIDS

Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity

(2014) T. Mesplede et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness

(2014) Melissa Wares et al.   Retrovirology

Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO

(2014) Jean-Michel Molina et al.   Journal of the International AIDS Society

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

(2013) Pedro Cahn et al.   LANCET

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

(2013) Francois Raffi et al.   LANCET

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

(2013) Thibault Mesplède et al.   Retrovirology

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

(2012) Joseph J. Eron et al.   JOURNAL OF INFECTIOUS DISEASES

Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes

(2011) Kendra E. Hightower et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir

(2011) P. K. Quashie et al.   JOURNAL OF VIROLOGY

In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

(2010) Masanori Kobayashi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Novel integrase inhibitors for HIV

(2010) Nicole Prada et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Impact of Y143 HIV-1 Integrase Mutations on Resistance to Raltegravir In Vitro and In Vivo

(2009) O. Delelis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY